Aim: Despite of huge development of molecular research and target agents, patients with EGFR wild type NSCLC who accounted for more than a half of NSCLC patients still have to receive platinum doublet chemotherapy in 1 st line treatment. Because only a little research has been conducted with EGFR wild type NSCLC patients, we investigated efficacies of various platinum doublet regimens in these patients. Methods: We retrospectively analyzed survival, response rate and prognostic factors of various platinum doublet regimens. Between 2007 and 2013, a total of 165 patients with EGFR wild type non-squamous NSCLC who received platinum doublet chemotherapy as 1 st line treatment at Korea University Guro Hospital were included in this study. Results: 71 (43%) patients treated with pemetrexed plus platinum (PP). 94 (57.0%) patients treated with non-pemetrexed plus platinum (NPP). Among the patients treated with NPP, 52(31.5%) patients treated with gemcitabine plus platinum and 37 (22.4%) patients treated with taxane plus platinum. Overall response rate was not different among the PP group and NPP group (26.8% versus 28.7%, p = 0.78). Median progression-free survival (PFS) and overall survival (OS) also showed no differences ( p = 0.07 for PFS, p = 0.82 for OS). The median PFS and median OS of PP group were 4.6 months (95% CI, 3.8-5.4) and 18.7 months (95% CI, 11.7-25.8) and NPP group were 6.2 months (95% CI, 3.4-5.0) and 12.2 months (95% CI, 10.3-14.1). In subgroup analysis, most subgroups showed statistically insignificant results in PFS and OS according to the chemotherapeutic regimens. In patients who treated with PP, stage I-III at diagnosis, metastasis confined to lung or pleura and treatment more than 2 nd line chemotherapy after 1 st line treatment related to prolonged OS. In patients who treated with the NPP, patients who had metastasis confined to lung and/or pleura and patients who treated more than 2 nd line chemotherapy after 1 st line treatment related with prolonged OS in multivariate analysis. Conclusions: Our data showed that the efficacy of various platinum doublet regimens was not different in EGFR wild type non-squamous NSCLC. Disclosure: All authors have declared no conflicts of interest.
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